Recurring Double Bottom patterns are evident Once price completes its current double bottom 1.70 is a good target for price to aim for
About: Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as...
CRIS has broken the daily downtrend with a strong impulse. I'm looking for a pullback, one more wave up and a big drop. Look to the price action for more details.